Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : La Jolla Diagnostics, Inc.(OTC BB: LAJD) -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (119)	9/15/1999 9:29:00 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 168

Trading at .10/.13...this out now... La Jolla Diagnostics' Subsidiary, DiagnosTech, Enters Sales Agreement for Eastern Europe LA JOLLA, Calif.--(BW HealthWire)--Sept. 15, 1999--La Jolla Diagnostics Inc. (OTCBB:LAJD - news) announced that its subsidiary, DiagnosTech Inc. has entered into a preliminary sales and marketing agreement for its TB test kit with Logistic Worldwide LLC. The agreement provides Logistics with an option for exclusive distribution rights within a territory including Poland, Slovak, Belarus, Estonia, Latvia and the Czech Republic. Under the terms of the agreement with DiagnosTech, Logistics is to complete registration of DiagnosTech's rapid test for active tuberculosis within 90 days. Provided that such registration can be obtained, Logistics will be required to purchase a minimum of 250,000 TB tests within the 12 months following registration in order to maintain their exclusive marketing rights. No assurance can be given that Logistics will be successful in obtaining the required local regulatory approvals within this timeframe, or that any subsequent purchases will be sufficient to maintain the exclusive sales and marketing agreement. TB represents a major threat to health throughout the world. Up to one-third of the world's population is infected with the organism responsible for TB, of which approximately 10% are expected to develop active disease and thus require treatment. The World Health Organization estimates that approximately 1 billion TB tests will be performed worldwide in the year 2000. La Jolla Diagnostics, through its DiagnosTech subsidiary, offers this rapid test for the detection of active tuberculosis disease. Unlike other tests designed to demonstrate infection, the DiagnosTech test is believed to demonstrate the presence of active disease. As such, the company feels it has the potential for widespread clinical acceptance as useful in determining which patients require treatment. The company is in the initial stages of preparing to submit data to the FDA as a prerequisite for marketing its TB test in the United States. All sales and marketing activities are currently limited to regions outside the U.S. Forward-looking statements in this release are made pursuant to the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties. Contact: La Jolla Diagnostics Inc. Don Brucker, 800/454-6790, Fax 619/454-7851 lajd.com lajd96@aol.com